-
Beovu Safety Developments Presented by JAMA Ophthalmology Medical Journal in November 2021
Meanwhile, Still Waiting for the Anticipated Beovu Label Change That Was Previewed by Novartis Back in May 2021 (Posted by Tom Lamb at Drug Injury Watch) As the year 2021 draws to an end, we…
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…
-
Philips Breathing Devices Recall Update: FDA Releases Explosive New Findings in November 2021
What Philips Knew and When, What Philips Did or Did Not Do, Much More, From the FDA Form 483 Inspection Report (Posted by Tom Lamb at Drug Injury Watch) We occasionally go "off-topic" on this…
-
Two Padcev SJS / TEN Case Reports Published Before March 2021 Padcev Label Change About These Skin Reactions
When Astellas Pharma First Knew About SJS / TEN Side Effects Is A Key Fact In This Still Developing Padcev Drug Safety Issue (Posted by Tom Lamb at Drug Injury Watch) About a month ago,…
-
Xeljanz Risks of Cardiovascular Events, as Well as Cancers, Cause More Xeljanz Use Limitations
October 2021 UK’s MHRA Xeljanz Action Follows September 2021 FDA Xeljanz Drug Safety Communication Update (Posted by Tom Lamb at Drug Injury Watch) On September 1, 2021, we posted this article, “Xeljanz: FDA Warnings Updated:…